E2F

[Cell Death & Disease] Researchers suggested that E2F transcription factor 2-activated DLEU2 may function as a competing endogenous RNA to facilitate prostate cancer progression by targeting the miR-582-5p/SGK1 axis.

[Scientific Reports] Researchers found heightened expression of RB-family (RBL) 2 and reduced expression of AURKA/B pathway genes was associated with improved outcomes in p53 wild-type but not p53 mutant NSCLC patients.

[Nature Communications] The authors indicated that KDM6B promoted an oncogenic CDK4/6-pRB-E2F pathway in neuroblastoma cells via H3K27me3-dependent enhancer-promoter interactions.

[Blood Advances] Researchers reported results of a phase Ib dose-escalation study of the novel, subcutaneous BET inhibitor RO6870810 combined with the BCL-2 inhibitor venetoclax, and rituximab, in recurrent/refractory diffuse large B cell lymphoma.

[Molecular Carcinogenesis] Scientists found that NUAK family kinase 2 (NUAK2) expression was elevated in prostate cancer and metastatic castration resistant PC versus normal tissue, and expression correlated with an increased risk of metastasis.

[Cancer Gene Therapy] Investigators uncovered that the transcription factor p53 could upregulate miR-519d-3p expression to directly suppress the expression of E2F transcription factor 1 (E2F1), thus inhibiting prostate cancer growth and metastasis.